Breuning VC, Bustillos VJ

Language: Spanish
References: 15
Page: 11-21
PDF size: 542.77 Kb.

ABSTRACT

A retrospective descriptive study is conducted at the San Juan de Dios Hospital, San José, Costa Rica, during the period from February 2016 to March 2017, with a total of 37 patients from which a combined screening during the first trimester of pregnancy was conducted, evaluating maternal age, biochemical and sonographic methods that together can predict the risk of fetal chromosomal alterations during pregnancy. The purpose of using combined screening as a non invasive method is to identify high risk ges- tations and to minimize the number of invasive procedures to detect the highest number of cases. Four patients with higher risk of aneuploidy during pregnancy were identified through this screening.

REFERENCES

1. Bustillos Villavicencio J. Protocolo: Ecografía de primer trimestre y screening de alteraciones cromosómicas y estructurales en el primer trimestre del embarazo. Servicio de Obstetricia, Hospital San Juan de Dios

2. Rao R., Platt L. D. Ultrasound screening: status of markers and efficacy of screening for structural abnormalities. Seminars in perinatology. WB Saunders. 2016; 67-78

3. Nicolaides KH, Heath V, Cicero S. Increased nuchal translucency at 11-14 weeks. Prenat Diagn 2002;22:308-315

4. Nicolaides KH, Sebire N, Snijders R. Nuchal translucency and chromosomal defects in: The 11-14 week scan. The diagnosis of fetal abnormalities. Diploma in fetal medicine series, Ed. KH Nicolaides. 1st Ed. London The Parthenon Publishing Group 1999 pp 3-65

5. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides KH. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001;358:1665- 1667

6. Howard C. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 2000;92:97-101

7. Souka A, Krampl E, Bakalis S, Heath V, Nicolaides KH. Outcome of pregnancies in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 2001;18:9-17

8. Souka A, Snjiders R, Novakov A, Soares W, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998;11:391-400

9. Chi T, Huggon I, Zosmer N, Nicolaides KH. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001;18:610-614

10. Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol 2003:21;313-321

11. Alfirevic Z, Sundberg K, Brigham Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev. 2003;(3):CD003252

12. Agathokleous, M., Chaveeva, P., Poon, L. C. Y., Kosinski, P., & Nicolaides, K. H. Meta ‐analysis of second‐trimester markers for trisomy 21. Ultrasound in Obstetrics & Gynecology. 2013; 41: 247-261

13. GHI, T., et al. ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis. Ultrasound in Obstetrics & Gynecology. 2016; 48: 256-268

14. Quezada M.S, Gil M.M, Francisco C., Oròsz G. & Nicolaides K.H. Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10- 11 weeks gestation and the combined test at 11-13 weeks.Ultrasound Obstet Gynecol. 2015; 45: 36-41.

15. Gil M.M., Quezada M.S., Revello R., Akolekar R., Nicolaides K.H. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015; 45: 249-266.